Chinese brain-computer interface startup Nuanxinjia raises ¥300M
What's the deal? Hangzhou-based Nuanxinjia (暖芯迦) has closed a ¥300M (~$41M) strategic funding round to advance its visual brain-computer interface (BCI) technology. The round was co-led by a prominent industrial investor and Legend Capital, with existing shareholder Fengnian Capital increasing its stake. GF Xinde and Caitong Capital also participated, while Qifeng Capital served as financial adviser.
The funds will go toward clinical trials for the company's visual BCI products and continued development of its core technology.
Why now? Brain-computer interfaces have surged into the global spotlight, driven by high-profile advances from Neuralink and a growing wave of government-backed neuroscience initiatives in China. Beijing has made BCI a priority within its broader push to lead in frontier technologies, creating a fertile funding environment for domestic players like Nuanxinjia.
What could go wrong? BCI remains an early-stage field where clinical and regulatory hurdles are steep. Visual BCI products must clear rigorous safety trials before commercialisation, and timelines can slip. Competition is intensifying both domestically and abroad, and the technology's path to widespread adoption is still uncertain.
The signal: Nuanxinjia's ¥300M round underscores how China's BCI sector is attracting serious institutional capital even at the clinical stage, with Legend Capital — one of the country's most prominent venture firms — co-leading alongside industrial backers. For context, Neuralink, currently at late growth stage according to Dealroom, has helped catalyse global investor interest in the space, and Chinese startups are now racing to match that momentum with domestic funding and government tailwinds.
Read more: jiemian.com
